Pre-made Elotuzumab benchmark antibody ( Whole mAb, anti-SLAMF7/CS1 therapeutic antibody, Anti-19A/CD319/CRACC Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Elotuzumab biosimilar, Whole mAb, Anti-SLAMF7/CS1 Antibody: Anti-19A/CD319/CRACC therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Elotuzumab, sold under the brand name Empliciti, is a humanized IgG1 monoclonal antibody medication used in combination with lenalidomide and dexamethasone, for adults that have received 1 to 3 prior therapies for the treatment of multiple myeloma. It is also indicated for adult patients in combination with pomalidomide and dexamethasone, who have received 2 prior therapies including lenalidomide and a protease inhibitor. Administration of elotuzumab is done intravenously. Each intravenous injection of elotuzumab should be premedicated with dexamethasone, diphenhydramine, ranitidine and acetaminophen. It is being developed by Bristol Myers Squibb and AbbVie.